NSAID Use in Ulcerative Colitis Treated With Mesalamine
NSAIDs such as ibuprofen are generally recommended to be avoided in patients with ulcerative colitis because NSAIDs can worsen UC symptoms or trigger flares. [1][2] Mesalamine labeling also warns that concurrent use with known nephrotoxic agents, including NSAIDs, may increase the risk of nephrotoxicity and that renal function should be monitored. [3]
Medication Selection Algorithm
For pain or inflammation in ulcerative colitis, preferred analgesic options commonly include non-NSAID agents such as acetaminophen, while NSAIDs such as ibuprofen are avoided. [1][2][4]
Clinical Guidance on Ibuprofen
Avoidance of NSAIDs in ulcerative colitis is specifically recommended by patient-directed clinical guidance from the NIDDK. [1] Mayo Clinic patient guidance similarly states that nonprescription NSAIDs, including ibuprofen, may trigger flares in patients with ulcerative colitis. [2]
Mesalamine-Specific Safety Considerations
Mesalamine prescribing information identifies NSAIDs as nephrotoxic agents that may increase the risk of nephrotoxicity when used concurrently. [3] Renal function monitoring is recommended in patients receiving mesalamine who are also taking nephrotoxic drugs such as NSAIDs. [3]
Practical Prescribing Decision
Ibuprofen should not be prescribed routinely for a patient taking mesalamine for ulcerative colitis. [1][2] If an NSAID is being considered despite UC guidance, risk–benefit assessment should incorporate renal risk based on mesalamine labeling and the UC guidance to avoid NSAIDs. [1][2][3]
Target Goals of Therapy Related to Pain Control
Pain control in ulcerative colitis should use non-NSAID strategies that avoid flare-provocation risk and minimize nephrotoxicity risk in patients receiving mesalamine. [1][2][3][4]